BlackRock, Inc. 13D and 13G filings for Taysha Gene Therapies, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Taysha Gene Therapies, Inc. TSHA | BlackRock Inc. BLK | 13,520,533 6.600% | 0 (Unchanged) | Filing |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | Taysha Gene Therapies, Inc. TSHA | BlackRock Inc. BLK | 13,520,533 6.600% | 12,474,043 (+1191.99%) | Filing |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Taysha Gene Therapies, Inc. TSHA | BlackRock Inc. BLK | 1,046,490 2.600% | -1,986,473 (-65.50%) | Filing |
| 2022-02-07 4:41 pm Purchase | 2021-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA | BlackRock Inc. BLK | 3,032,963 7.900% | 803,147 (+36.02%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA | BlackRock Inc. BLK | 2,229,816 5.900% | 2,229,816 (New Position) | Filing |